NL-OMON44238已完成不适用
A First-in-Human Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of LTI-291 in Healthy Subjects - Single Ascending Dose study of LTI-291
ysosomal Therapeutics Incorperated.0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Signed informed consent prior to any study-mandated procedure.
- •2. Healthy male or female subjects of non-childbearing potential (defined as postmenopausal with amenorrhea for at least 12 months) or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy, 18 to 65 years of age (inclusive) at screening.
- •3. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and with a minimum weight of 50 kg at screening.
- •4. All males must practice effective contraception and abstain from sperm donation during the study and be willing and able to continue contraception and abstain from sperm donation for at least 90 days after their last dose of study treatment.
- •5. Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
排除标准
- •1. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature), 12-lead electrocardiogram (ECG), and clinical laboratory parameters (hematology, blood chemistry, and urinalysis)). Minor deviations of laboratory values from the normal range may be accepted, if judged by the Investigator to have no clinical relevance.
- •2. Clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •3. Positive Hepatitis B surface antigen (HBsAg), Hepatitis B antibodies, Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- •4. Systolic blood pressure (SBP) greater than 150 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 95 or less than 50 mm Hg at screening or baseline.
- •5. Abnormal findings in the resting ECG at screening defined as:
- •a. QTcF > 450 msec for males or > 470 msec for females;
- •b. Notable resting bradycardia (HR < 40 bpm) or tachycardia (HR > 100 bpm);
- •c. QRS > 120 msec;
- •d. Personal or family history of congenital long QT syndrome or sudden death;
- •e. ECG with QRS and/or T wave judged to be unfavorable for a consistently accurate QT measurement (e.g., neuromuscular artefact that cannot be readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T- and U-waves, prominent U waves);
- •f. Evidence of atrial fibrillation, atrial flutter, complete branch block, Wolf-Parkinson-White Syndrome, or cardiac pacemaker.
- •6. Use of any medications (prescription or over-the-counter [OTC]), within 14 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions are paracetamol (up to 4 g/day) and ibuprofen (up to 1g/day). Other exceptions will only be made if the rationale is clearly documented by the investigator. No exceptions will be made for any known inducer or inhibitor of CYP3A4, CYP1A2 or CYP2D6.
- •7. Use of any vitamin, mineral, herbal, and dietary supplements within 7 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions will only be made if the rationale is clearly documented by the investigator.
- •8. Participation in an investigational drug or device study within 3 months prior to first dosing.
- •9. History of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units of alcohol per week, drug abuse, or regular use of sedatives, hypnotics, tranquillizers, or any other addictive agent.
- •10. Positive test for drugs of abuse at screening or pre-dose.
- •11. Use of tobacco or nicotine products within 14 days before the first dose administration.
- •12. Demonstrates an excess in xanthine consumption (more than eight cups of coffee or equivalent per day).
- •13. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or
研究者
相似试验
已完成
1 期
A study to assess the safety and tolerability of ACI-3024 and how the drug affects and interacts with the bodyISRCTN18150742AC Immune (Switzerland)80
进行中（未招募）
1 期
Testing the safety and effects of a new study drug (GCG-06) in adult subjects (GCG-06 - first doses in human)Nutritional, Metabolic, EndocrineObesityISRCTN69500549Imperial College London54
进行中（未招募）
1 期
A study to test the safety and effectiveness of bacteria called Bifidobacterium breve in adults with asthmaAsthmaEUCTR2018-003242-16-GB4D pharma plc90
已完成
不适用
A First-in-Human, randomized, double-blind, placebo-controlled ascending dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324 in healthy subjects.PainNL-OMON46459Stragen France78
招募中
1 期
A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZE50 0134 in Healthy VolunteersChronic lymphocytic leukemia (CLL)Cancer - Leukaemia - Chronic leukaemiaACTRN12624000093583Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)40